Of course there are significant markets in fatty liver disease and viral hepatitis - however, quantifying liver fat is likely to be relevant in only limited numbers of trials, and from a clinical perspective is not something that I, as a practicing liver specialist, see any great value in. Quantifying liver fibrosis would be very useful, but RHT can't actually do this at present. If you base your investment decisions on unsubstantiated company announcements then you might as well invest in the likes of Continental Coal or the ilk.
RHT Price at posting:
3.2¢ Sentiment: None Disclosure: Not Held
